ICICI Direct is bullish on Sun Pharmaceutical Industries has recommended buy rating on the stock with a target price of Rs 625 in its research report dated August 02, 2020.
ICICI Direct's research report on Sun Pharmaceutical Industries
Revenues de-grew 9.4% YoY to Rs 7585 crore (I-direct estimate: Rs 7948 crore) mainly due to 27.5% YoY decline in US formulations to Rs 2136 crore due to high base and continued pressure on dermatology segment (Taro included). India business grew 3.2% YoY to Rs 2388 crore whereas Emerging Markets business de-grew 2.4% YoY to Rs 1316 crore. RoW markets business also de-grew 11.1% YoY to Rs 1030 crore. EBITDA margins expanded 47 bps YoY, 765 bps QoQ to 24.3% (I-direct estimate: 17.0%) despite higher employee expenses mainly due to lower other expenditure and better gross margins. EBITDA de-grew 7.6% YoY to Rs 1844 crore (I-direct estimate: Rs 1351 crore). Adjusted PAT de-grew 17.4% YoY to Rs 1146 crore (I-direct estimate: Rs 621 crore). Exceptional expense of Rs 3633 crore pertain to Taro's settlement with US DoJ (cumulative US$419 million) and US$60 million provision for multi-jurisdiction antitrust matters.
This would have positive implications for margins also as we expect faster absorption of frontloaded costs on the specialty front. We maintain BUY and arrive at our new target price of Rs 625 based on 26x FY22E EPS of Rs 24.1.
For all recommendations report, click here
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.